Dr. Hang Zheng 郑航
Chief Physician, Associate Professor
Department of Medical Oncology, Nanfang Hospital, Southern Medical University, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment, immunotherapy, and nutritional support for cancers including nasopharyngeal, breast, lung, esophageal, gastrointestinal, cervical, ovarian, prostate, bladder, thymoma, melanoma, and sarcoma. Focuses on integrated Chinese-Western medicine, targeted therapy, and personalized care.
Dr. Zheng holds an MD and has worked at Nanfang Hospital since 1988, helping establish its Oncology Department. With over 30 years of experience, Dr. Zheng leads six research projects, including CSCO initiatives, and has published over 60 papers. Awards include two Third-Class Military Science and Technology Progress Awards.
Professional roles
- Guest Editor, Chinese Journal of Clinical Rehabilitation
- Standing Committee Member, Traditional Medicine Professional Committee, Guangdong Anti-Cancer Association
- Member, Oncology Professional Committee, Guangdong Association of Integrative Traditional Chinese and Western Medicine
- Director, Drug Clinical Trial Research Ward, Nanfang Hospital
Name order: in Chinese the family name comes first (Zheng Hang). Papers usually list the name as Hang Zheng or Zheng H.
Selected publications
34 papers on PubMed matched by name and affiliation; 3 as first or senior author since 2016. Most recent first- or senior-author papers:
- Oncotarget, 2017 (senior author): Casticin attenuates liver fibrosis and hepatic stellate cell activation by blocking TGF-β/Smad signaling pathway. PubMed 28915589
- Exp Cell Res, 2017 (senior author): Different functions of DEPTOR in modulating sensitivity to chemotherapy for esophageal squamous cell carcinoma. PubMed 28267437
- Oncotarget, 2016 (senior author): Elevation of n-3/n-6 PUFAs ratio suppresses mTORC1 and prevents colorectal carcinogenesis associated with APC mutation. PubMed 27769066
- Cancer Prev Res (Phila), 2014 (first author): Inhibition of endometrial cancer by n-3 polyunsaturated fatty acids in preclinical models. PubMed 24866178
- Oncol Rep, 2013 (senior author): Heparanase is involved in the proliferation and invasion of nasopharyngeal carcinoma cells. PubMed 23467769
- Nan Fang Yi Ke Da Xue Xue Bao, 2012 (senior author): [Granzyme B-VEGF receptor-binding peptide fusion protein expressed in B. longum induces apoptosis of KDR-positive cells]. PubMed 22820600
- Cancer Lett, 2010 (first author): Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells. PubMed 20554106
- Nan Fang Yi Ke Da Xue Xue Bao, 2006 (first author): [Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer]. PubMed 16762887
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion